Đang chuẩn bị liên kết để tải về tài liệu:
Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The peritoneum is one of the most frequent sites of recurrent gastric carcinoma after curative treatment, despite the administration of pre- and/or postoperative systemic chemotherapy. Indeed, the prognosis of peritoneal carcinomatosis from gastric carcinoma continues to be poor, with a median survival of less than one year with systemic chemotherapy. |

TÀI LIỆU LIÊN QUAN

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Surgical treatment results of gastric cancer in the lower third of the stomach

Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: A propensity score-matched analysis

Evaluating the efcacy and microenvironment changes of HER2+gastric cancer during HLX02 and Endostar treatment using quantitative MRI

Early outcomes of surgical treatment with perioperative chemotherapy for gastric cancer

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): A phase II study (GASPAR)

Clinical and paraclinical characteristics of locally advanced distal gastric adenocarcinoma patients underwent the treatment of postoperative adjuvant chemoradiotherapy at Hue Central Hospital

Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Prognostic factors for overall survival in stage IV gastric cancer